CBD Research For The Treatment Of Cancer
In the United States, cannabinoids have been allowed for use in palliative medicine due to their effectiveness for pain-relief and effectiveness against vomiting and nausea, but increasing number of research studies have investigated and indicated their anticancer properties.
Research from the NCBI
The National Center for Biotechnology Information (NCBI) advances science and health by providing access to biomedical and genomic information. PubMed, one of many resources on NCBI’s website comprises more than 28 mission citations or biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher websites.
The following is a partial list of cancer research studies which have been published on the NCBI’s website.
General Cancer Research
Cannabidiol as potential anticancer drug
https://www.ncbi.nlm.nih.gov/pubmed/22506672
Cannabidiol inhibits angiogenesis by multiple mechanisms
https://www.ncbi.nlm.nih.gov/pubmed/22624859
The inhibitory effects of cannabidiol on systemic malignant tumors
https://www.ncbi.nlm.nih.gov/pubmed/23544909
Cannabidiol inhibits cancer cell invasion via up regulation of tissue inhibitor of matrix metalloproteinases-1
https://www.ncbi.nlm.nih.gov/pubmed/19914218
Lung Cancer Research
Cannabidiol inhibits lung cancer cell invasion and metastasis via intercellular adhesion molecule-1C
https://www.ncbi.nlm.nih.gov/pubmed/22198381
COX-2 and PPAR-γ confer cannabidiol-induced apoptosis of human lung cancer cells
https://www.ncbi.nlm.nih.gov/pubmed/23220503
Decrease of plasminogen activator inhibitor-1 may contribute to the anti-invasive action of cannabidiol on human lung cancer cells
https://www.ncbi.nlm.nih.gov/pubmed/20668920
Prostate / Colon Cancer Research
Towards the use of non-psychoactive cannabinoids for prostate cancer
https://www.ncbi.nlm.nih.gov/pubmed/22849856
Induction of apoptosis by cannabinoids in prostate and colon cancer cells is phosphatase dependent
https://www.ncbi.nlm.nih.gov/pubmed/22110202
Chemo preventive effect of the non-psychotropic phytocannabinoid cannabidiol on experimental colon cancer
https://www.ncbi.nlm.nih.gov/pubmed/22231745
Breast Cancer Research
Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma
https://www.ncbi.nlm.nih.gov/pubmed/16728591
Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross talk between apoptosis and autophagy
https://www.ncbi.nlm.nih.gov/pubmed/21566064
Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis
https://www.ncbi.nlm.nih.gov/pubmed/20859676
Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells
https://www.ncbi.nlm.nih.gov/pubmed/18025276
Cannabidiolic acid, a major cannabinoid in fiber-type cannabis, is an inhibitor of MDA-MB-231 breast cancer cell migration
https://www.ncbi.nlm.nih.gov/pubmed/22963825
Glioblastoma / Brain Cancer Research
Cannabidiol enhances the inhibitory effects of delta9-tetrahydrocannabinol on human glioblastoma cell proliferation and survival
https://www.ncbi.nlm.nih.gov/pubmed/20053780
Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines(PubMed)
https://www.ncbi.nlm.nih.gov/pubmed/14617682
Systematic review of the literature on clinical and experimental trials on the antitumor effects of cannabinoids in gliomas
https://www.ncbi.nlm.nih.gov/pubmed/24142199
Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor-independent mechanism
https://www.ncbi.nlm.nih.gov/pubmed/15700028
Id-1 is a key transcriptional regulator of glioblastoma aggressiveness and a novel therapeutic target
https://www.ncbi.nlm.nih.gov/pubmed/23243024
Triggering of the TRPV2 channel by cannabidiol sensitizes glioblastoma cells to cytotoxic chemotherapeutic agents
https://www.ncbi.nlm.nih.gov/pubmed/23079154
Cannabidiol, a non-psychoactive cannabinoid compound, inhibits proliferation and invasion in U87-MG and T98G glioma cells through a multitarget effect
https://www.ncbi.nlm.nih.gov/pubmed/24204703
Local delivery of cannabinoid-loaded microparticles inhibits tumor growth in a murine xenograft model of glioblastoma multiforme
https://www.ncbi.nlm.nih.gov/pubmed/23349970
Leukemia Cancer Research
Cannabidiol-induced apoptosis in human leukemia cells: A novel role of cannabidiol in the regulation of p22phox and Nox4 expression
https://www.ncbi.nlm.nih.gov/pubmed/16754784
Cannabidiol-Induced Apoptosis in Human Leukemia Cells
https://www.ncbi.nlm.nih.gov/pubmed/?term=Cannabidiol-Induced+Apoptosis+in+Human+Leukemia+Cells
Skin Cancer Research
Anticancer activity of anandamide in human cutaneous melanoma cells
https://www.ncbi.nlm.nih.gov/pubmed/24041928
Kaposi Sarcoma Cancer Research
Cannabidiol inhibits growth and induces programmed cell death in Kaposi Sarcoma-associated herpes virus-infected endothelium (PubMed)
https://www.ncbi.nlm.nih.gov/pubmed/23264851
Endocrine Cancer Research
Endocannabinoids in endocrine and related tumors
https://www.ncbi.nlm.nih.gov/pubmed/18508995
A comparative study on cannabidiol-induced apoptosis in murine thymocytes and EL-4 thymoma cells
https://www.ncbi.nlm.nih.gov/pubmed/18387516
Bladder Cancer Research
TRPV2 activation induces apoptotic cell death in human T24 bladder cancer cells: a potential therapeutic target for bladder cancer
https://www.ncbi.nlm.nih.gov/pubmed/20546877
Pain in Cancer Patients Research
Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC: CBD extract and THC extract in patients with intractable cancer-related pain
https://www.ncbi.nlm.nih.gov/pubmed/19896326
Nabiximols for opioid-treated cancer patients with poorly controlled chronic pain: a randomized, placebo-controlled, graded-dose trial
https://www.ncbi.nlm.nih.gov/pubmed/22483680
About Diverse Biotech, Inc.
Diverse Biotech Inc. is an innovative, clinical-stage biopharmaceutical research company, committed to discovering and developing novel therapeutics from its proprietary cannabinoid product platform.
For more information on Diverse Biotech or its Cannabinoid (CBD) clinical trials, use in the treatment of specific types of malignancies related to glioblastoma, myeloma, gastrointestinal, and breast cancer, when administered in conjunction with Standard of Care, please contact Diverse Biotech by phone at 407-776-9217 or visit the company’s headquarters at 805 S. Kirkman Rd, Suite 202, Orlando, Florida 32811.